New antibodies recognizing p73: Comparison with commercial antibodies

A. Emre Sayan, Andrea Paradisi, Borek Vojtesek, Richard A. Knight, Gerry Melino, Eleonora Candi

Research output: Contribution to journalArticlepeer-review


p73, unlike p53, is expressed as a number of isomeric forms. Alternative splicing at the 3′ end of p73 transcript, together with the usage of a second promoter downstream of exon 3, can generate up to 24 p73 isoforms. Variants lacking the TA domain (ΔN isoforms) are induced by TAp73 and by p53, and inhibit their transcriptional activity. However, understanding the complex biology of p73 has been handicapped by the lack of high affinity specific antibodies for the different isoforms. Here, we report the characterization, by Western blotting and immunoprecipitation, of three new polyclonal antisera recognizing all p73 isoforms, only ΔN isoforms or only p73α, and which have advantages of affinity and specificity over previously available antibodies.

Original languageEnglish
Pages (from-to)186-193
Number of pages8
JournalBiochemical and Biophysical Research Communications
Issue number1
Publication statusPublished - Apr 29 2005


  • Apoptosis
  • DNA damage
  • p53
  • p53 family
  • p73
  • TP73

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Fingerprint Dive into the research topics of 'New antibodies recognizing p73: Comparison with commercial antibodies'. Together they form a unique fingerprint.

Cite this